Alexion replaces CFO Clancy and his 'legendary caution.' Could an M&A spree follow? | Fierce Pharma
Amgen close to deal to buy Horizon Therapeutics for $20bn | Financial Times
Should Amgen Finally Buy Alexion Pharmaceuticals? | The Motley Fool
Amgen is targeting $BCRX for Acquisition : r/BCRX
Alexion Higher on Spanish Report, Cited by Analyst, That Amgen Will Make Bid - TheStreet
Alexion Pharmaceuticals: In The News And Moving Higher (NASDAQ:ALXN) | Seeking Alpha
Amgen targets rare diseases with acquisition - BioStock
Alexion Settles With Amgen Over Eculizumab Patents
Amgen readies case for Soliris copycat as 2025 launch looms
Amgen reports pair of positive clinical trial results | Pacific Coast Business Times
Alexion Pharmaceuticals: Patented Quality at a Great Price | by Shivam Kollur | Medium
Alexion Is Undervalued And Ripe For Acquisition | The Healthcare Technology Report.
Amgen Played Waiting Game Before Agreeing $3.7bn ChemoCentryx Deal :: Scrip
USPTO agrees to Amgen's petition to review Alexion's patents on rare disease drug - MedCity News
Amgen Drops Alexion Blood Drug IPRs, Gets 2025 License
Paroxysmal Nocturnal Hemoglobinuria Therapeutics Market Is Booming Worldwide 2022-2028 | Alexion Pharmaceuticals, Akari therapeutics, Apellis Pharmaceuticals, Amgen Inc - Digital Journal
FDA accepts Alexion's application for next-generation PNH drug - MedCity News
All 'Alexion Pharmaceuticals' news | Silicon Republic
Alexion and Amgen Settle IPRs Over SOLIRIS (eculizumab) - Big Molecule Watch
Could Amgen soften the Neulasta biosimilar blow with an Alexion buy? | Fierce Pharma
Amgen strikes out for the Horizon | Evaluate
Best Biotechnology Stocks To Watch: Alexion, Merck, Amgen, Emergent | Investing.com
